Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy R Simpson

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor controlGuy R Simpson, Robert S Coffin
Frontiers in Oncology|March 6, 2020
Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic ResponseNicola E Annels, Guy R Simpson, Hardev Pandha
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21Kate Relph, Mehreen Arif, Hardev Pandha, et al.
Oncolytic Virotherapy|September 1, 2016
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesGuy R Simpson, Kate Relph, Kevin Harrington, et al.
Scientific Reports|March 28, 2019
Membrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stromaNatasha Punia, Monika Primon, Guy R Simpson, et al.
BMC Cancer|September 15, 2010
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivoAnna-Maria Anesti, Guy R Simpson, Toby Price, et al.
Cancer Research|May 3, 2006
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor controlGuy R Simpson, Ziqun Han, Binlei Liu, et al.
BMC Urology|February 7, 2014
Targeting HOX transcription factors in prostate cancerRichard Morgan, Angie Boxall, Kevin J Harrington, et al.
Breast Cancer Research and Treatment|October 12, 2012
Targeting the HOX/PBX dimer in breast cancerRichard Morgan, Angie Boxall, Kevin J Harrington, et al.
The Journal of General Virology|December 26, 2001
Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regionsKarin Mattsson, Csaba Kiss, Georgina M Platt, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor controlGuy R Simpson, Robert S Coffin
Frontiers in Oncology|March 6, 2020
Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic ResponseNicola E Annels, Guy R Simpson, Hardev Pandha
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21Kate Relph, Mehreen Arif, Hardev Pandha, et al.
Oncolytic Virotherapy|September 1, 2016
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesGuy R Simpson, Kate Relph, Kevin Harrington, et al.
Scientific Reports|March 28, 2019
Membrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stromaNatasha Punia, Monika Primon, Guy R Simpson, et al.
BMC Cancer|September 15, 2010
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivoAnna-Maria Anesti, Guy R Simpson, Toby Price, et al.
Cancer Research|May 3, 2006
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor controlGuy R Simpson, Ziqun Han, Binlei Liu, et al.
BMC Urology|February 7, 2014
Targeting HOX transcription factors in prostate cancerRichard Morgan, Angie Boxall, Kevin J Harrington, et al.
Breast Cancer Research and Treatment|October 12, 2012
Targeting the HOX/PBX dimer in breast cancerRichard Morgan, Angie Boxall, Kevin J Harrington, et al.
The Journal of General Virology|December 26, 2001
Latent nuclear antigen of Kaposi's sarcoma herpesvirus/human herpesvirus-8 induces and relocates RING3 to nuclear heterochromatin regionsKarin Mattsson, Csaba Kiss, Georgina M Platt, et al.
Pageof 2